Peter Schneider, MD, discussed the latest investigational device exemption (IDE) study of the DETOUR System, dubbed the US IDE DETOUR II Clinical Trial, which is currently recruiting across 37 sites in the U.S., Germany, Poland, and Latvia.
Peter Schneider, MD, discussed the latest investigational device exemption (IDE) study of the DETOUR System, dubbed the US IDE DETOUR II Clinical Trial, which is currently recruiting across 37 sites in the U.S., Germany, Poland, and Latvia.
Peter Schneider, MD, discussed...